PDCD1 and Hodgkins lymphoma: showed that LAG3 inhibits the anti-tumor effect of anti-PD-1 and anti-LAG3 therapy in HL by inhibiting the CD4+ T cell responses (73), and that chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) shows little therapeutic effect with higher infiltration of LAG3+TILs.